{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-22-027801","form_type":"8-K","ticker":"NAGE","cik":"0001386570","company_name":"Niagen Bioscience, Inc.","filed_at":"2022-11-02T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.405305+00:00","generated_at":"2026-06-22T13:00:55.174094+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"ChromaDex Q3 net sales $17.1M, net loss narrows to $1.0M; approaches cash flow breakeven","bullets":["Net loss of $1.0M ($0.01 loss per share) vs $8.8M loss in Q3 2021; Adjusted EBITDA loss narrowed to $1.2M.","Gross margin 59.8% (down from 61.1% YoY); operating expenses cut $6.1M to $13.3M, driven by lower legal and marketing costs.","Signed long-term supply agreement with Nestlé Health Science with ~$2.0M initial purchase commitment; raised $7.7M from Nestlé and strategic investors.","JV signed to pursue Blue Hat approval for Tru Niagen in Mainland China; clinical study in JACC found Niagen safe in heart failure patients.","Tru Niagen e-commerce sales steady but B2B sales declined due to COVID-19 headwinds and macro factors."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-22-027801","json":"https://secwatch.observer/filing/0001628280-22-027801.json","markdown":"https://secwatch.observer/filing/0001628280-22-027801.md","text":"https://secwatch.observer/filing/0001628280-22-027801.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022027801/0001628280-22-027801-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022027801/cdxc-20221102.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-22T13:00:55.174094+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"aba828a709b1d8b655e15ca8f28dd9eebe8929d9","claim":"Niagen Bioscience, Inc. reported the quarter ended September 30, 2022 results: revenue $17.1 million, net income $1.0 million or $(0.01) per share, EPS $(0.01) per share.","evidence_excerpt":"ChromaDex Corporation Reports Third Quarter 2022 Financial Results Total net sales of $17.1 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1386570/000162828022027801/0001628280-22-027801-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended September 30, 2022"},{"label":"Revenue","value":"$17.1 million"},{"label":"Net income","value":"$1.0 million or $(0.01) per share"},{"label":"EPS","value":"$(0.01) per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}